mn 553 Pharmacology final exam review questions with answers

mn 553 Pharmacology final exam review
|\ |\ |\ |\ |\ |\




questions with answers |\ |\




regulations - CORRECT ANSWERS ✔✔∙all states have title |\ |\ |\ |\ |\ |\ |\ |\



protection for NPs |\ |\




•the board of nursing regulates practice
|\ |\ |\ |\ |\ |\




-5 states have joint oversight with medical board
|\ |\ |\ |\ |\ |\ |\ |\




•scope of practice is determined by NP license
|\ |\ |\ |\ |\ |\ |\




investigational new drug (IND) - CORRECT ANSWERS |\ |\ |\ |\ |\ |\ |\



✔✔•required before an investigational drug or bio product |\ |\ |\ |\ |\ |\ |\



can be administered to a human
|\ |\ |\ |\ |\ |\ |\




•the IND app is a compilation of all known information
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\



about the compound |\ |\ |\




•it also includes a description of the clinical research plan
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\



for the product
|\ |\ |\




•specific protocol for phase I study |\ |\ |\ |\ |\




phases of clinical study - CORRECT ANSWERS ✔✔•phase I
|\ |\ |\ |\ |\ |\ |\ |\



clinical eval is the 1st testing of a new compound in
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\



subjects for the purpose of establishing the tolerance of
|\ |\ |\ |\ |\ |\ |\ |\ |\



healthy human subjects |\ |\ |\

,•phase II clinical eval is controlled studies performed on
|\ |\ |\ |\ |\ |\ |\ |\ |\



pts having the target disease or disorder to determine a
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\



compound's potential usefulness and short term risks |\ |\ |\ |\ |\ |\




•phase III trials are controlled and uncontrolled clinical
|\ |\ |\ |\ |\ |\ |\ |\



trials of a drug's safety and efficacy in hospital and outpt
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\



settings |\




•phase III trials verify that the acceptable risk/benefit
|\ |\ |\ |\ |\ |\ |\ |\



ratio seen in II persists under conditions of anticipated
|\ |\ |\ |\ |\ |\ |\ |\ |\



usage in groups of pts large enough to identify
|\ |\ |\ |\ |\ |\ |\ |\ |\



statistically and clinically significant responses |\ |\ |\ |\




clinical judgment in prescribing - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\



✔✔•is there clear indication for drug?
|\ |\ |\ |\ |\ |\




•what drugs are effective for the disease?
|\ |\ |\ |\ |\ |\ |\




•what are the goals of therapy?
|\ |\ |\ |\ |\ |\




•monitoring to see if drug is meeting goals |\ |\ |\ |\ |\ |\ |\ |\




•duplications in med pts is taking |\ |\ |\ |\ |\ |\




•otc vs prescription
|\ |\ |\




•cost |\




•sources of info |\ |\




the process of prescribing - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\



✔✔•identify the pts problem |\ |\ |\ |\




•specify the therapeutic objective |\ |\ |\ |\

, •collab with the pt |\ |\ |\




•choose the treatment |\ |\ |\




•edu the pt
|\ |\ |\




•mt for effectiveness
|\ |\ |\




•individualize drug choice |\ |\




special population: pregnancy - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\



✔✔•avoid ACEI, consider BB |\ |\ |\ |\




•bulk laxative|\




special population: nursing moms - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\



✔✔avoid ACEI, consider BB |\ |\ |\




special population: pediatric - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\



✔✔•best pharmaceuticals for children act (BPCA)
|\ |\ |\ |\ |\ |\




•authorizes research to promote efficacy and safety
|\ |\ |\ |\ |\ |\




special population: older adults - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\



✔✔•beers criteria |\ |\




-looks at potential risk
|\ |\ |\ |\




-does not look at effectiveness
|\ |\ |\ |\